All In Biotech

NDA 212099 · Bayer Healthcare

Nubeqa

Darolutamide · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jul 30, 2019

Approved uses

4

Original approval plus efficacy supplements

Registered trials

130

30 Phase 3, 58 recruiting

FAERS reports

5,923

4,112 serious, 708 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 28, 2026.

NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. ( 1 ) NUBEQA is indicated for the treatment of adult patients with: non-metastatic castration resistant prostate cancer (nmCRPC) metastatic castration-sensitive prostate cancer (mCSPC) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.

Mechanism: Darolutamide is an androgen receptor (AR) inhibitor. Darolutamide competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. A major metabolite, ketodarolutamide, exhibited similar in vitro activity to darolutamide. In addition, darolutamide functioned as a progesterone receptor (PR) antagonist in vitro (approximately 1% activity compared to AR). Darolutamide decreased prostate cancer cell proliferation in vitro and tumor volume in mouse xenograft models of prostate cancer.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 3, 2025 Supplement 8 · Efficacy LetterLabel
  • Aug 5, 2022 Supplement 2 · Efficacy · priority review LetterLabel
  • Jan 7, 2021 Supplement 1 · Efficacy · priority review LetterLabel
  • Jul 30, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • NUBEQA · DAROLUTAMIDE 300MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Darolutamide" as an intervention, any sponsor and status, largest first.

All 130 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue881
  • hot flush662
  • death456
  • asthenia376
  • dizziness257
  • prostatic specific antigen increased249
  • arthralgia245
  • diarrhoea242
  • incorrect dose administered215
  • product dose omission issue213
  • dyspnoea208
  • neuropathy peripheral207

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201934
2020152
2021204
2022316
2023722
20241,405
20251,987
20261,103

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nubeqa (Darolutamide)

2024 spending

$998M

Beneficiaries

11,577

78,077 claims

Per beneficiary

$86,211

$110.35 per unit

View as table
YearSpending
2020$99,928,016
2021$223,521,256
2022$322,342,011
2023$576,350,299
2024$998,066,130

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 130 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.